KR102519869B1 - 골형성단백질의 치료적 용도 - Google Patents

골형성단백질의 치료적 용도 Download PDF

Info

Publication number
KR102519869B1
KR102519869B1 KR1020177003531A KR20177003531A KR102519869B1 KR 102519869 B1 KR102519869 B1 KR 102519869B1 KR 1020177003531 A KR1020177003531 A KR 1020177003531A KR 20177003531 A KR20177003531 A KR 20177003531A KR 102519869 B1 KR102519869 B1 KR 102519869B1
Authority
KR
South Korea
Prior art keywords
bmp
ser
leu
pro
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177003531A
Other languages
English (en)
Korean (ko)
Other versions
KR20170029576A (ko
Inventor
니콜라스 더블유 모렐
웨이 리
폴 디 업튼
Original Assignee
캠브리지 엔터프라이즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51453948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102519869(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 캠브리지 엔터프라이즈 리미티드 filed Critical 캠브리지 엔터프라이즈 리미티드
Priority to KR1020237010855A priority Critical patent/KR20230049757A/ko
Publication of KR20170029576A publication Critical patent/KR20170029576A/ko
Application granted granted Critical
Publication of KR102519869B1 publication Critical patent/KR102519869B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177003531A 2014-07-10 2015-07-09 골형성단백질의 치료적 용도 Active KR102519869B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237010855A KR20230049757A (ko) 2014-07-10 2015-07-09 골형성단백질의 치료적 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1412290.7A GB201412290D0 (en) 2014-07-10 2014-07-10 Novel use
GB1412290.7 2014-07-10
PCT/GB2015/051989 WO2016005756A1 (en) 2014-07-10 2015-07-09 Therapeutic use of bone morphogenetic proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010855A Division KR20230049757A (ko) 2014-07-10 2015-07-09 골형성단백질의 치료적 용도

Publications (2)

Publication Number Publication Date
KR20170029576A KR20170029576A (ko) 2017-03-15
KR102519869B1 true KR102519869B1 (ko) 2023-04-07

Family

ID=51453948

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177003531A Active KR102519869B1 (ko) 2014-07-10 2015-07-09 골형성단백질의 치료적 용도
KR1020237010855A Ceased KR20230049757A (ko) 2014-07-10 2015-07-09 골형성단백질의 치료적 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237010855A Ceased KR20230049757A (ko) 2014-07-10 2015-07-09 골형성단백질의 치료적 용도

Country Status (22)

Country Link
US (4) US10336800B2 (enExample)
EP (3) EP3669886B1 (enExample)
JP (1) JP6737770B2 (enExample)
KR (2) KR102519869B1 (enExample)
CN (1) CN106661094B (enExample)
AU (1) AU2015287397B2 (enExample)
CA (1) CA2954221C (enExample)
CY (2) CY1123011T1 (enExample)
DK (2) DK3669886T3 (enExample)
ES (2) ES2876124T3 (enExample)
GB (1) GB201412290D0 (enExample)
HR (2) HRP20200418T1 (enExample)
HU (2) HUE048924T2 (enExample)
LT (2) LT3669886T (enExample)
MX (2) MX378431B (enExample)
PL (2) PL3669886T3 (enExample)
PT (2) PT3669886T (enExample)
RS (2) RS60181B1 (enExample)
RU (1) RU2733318C2 (enExample)
SI (2) SI3166628T1 (enExample)
SM (2) SMT202000171T1 (enExample)
WO (1) WO2016005756A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
AU2018214629A1 (en) * 2017-02-06 2019-08-22 Acceleron Pharma Inc. Compositions and methods for treating heart failure
CN111344306A (zh) 2017-11-02 2020-06-26 拜耳股份公司 结合alk-1和bmpr-2的双特异性抗体
CN107760779B (zh) * 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
CN111527106B (zh) * 2017-12-12 2024-10-25 协和麒麟株式会社 抗bmp10抗体和以该抗体为有效成分的对高血压和高血压性疾病的治疗剂
CN111939245B (zh) * 2019-05-16 2024-03-01 龚笑海 一种心脏治疗和保护的药物组合物
EP4081240A4 (en) * 2019-12-03 2023-12-06 Acceleron Pharma Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONARY HYPERTENSION
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
WO2023012318A1 (en) * 2021-08-05 2023-02-09 Actelion Pharmaceuticals Ltd Bmp9 variant polypeptides and uses thereof
CN114317604B (zh) * 2022-03-04 2022-06-17 中国医学科学院阜外医院 一种自发性肺动脉高压模型及构建方法
CN120586063A (zh) * 2025-06-18 2025-09-05 中国人民解放军总医院第六医学中心 Bmp9抑制剂在制备用于治疗高血压的药物中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171355A (en) * 1875-12-21 Improvement in driers
DK0592562T3 (da) 1991-06-25 1999-08-30 Genetics Inst BMP-9-præparater
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
AU677849B2 (en) 1993-05-12 1997-05-08 Genetics Institute, Llc BMP-10 compositions
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
WO1996039431A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Bone morphogenic protein-10
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1571159A1 (en) † 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
US7741284B2 (en) 2004-05-12 2010-06-22 Acceleron Pharma Inc. BMP10 propeptides and related methods
WO2006130022A1 (en) 2005-05-30 2006-12-07 Agresearch Limited Modulation of ovulation by agonists and antagonists of bmprii
JP2009544325A (ja) 2006-07-27 2009-12-17 セントカー・インコーポレーテツド Ｂｍｐ−７変異体組成物、方法および使用
WO2008057461A2 (en) 2006-11-02 2008-05-15 Acceleron Pharma, Inc. Alk1 receptor and ligand antagonists and uses thereof
CA2685306A1 (en) * 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
US8999928B2 (en) 2009-04-01 2015-04-07 Indiana University Research And Technology Corporation Methods for treating diseases using a bone morphogenetic protein
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
EP2670847B1 (en) * 2011-02-03 2016-10-05 XOMA Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
CN108178789B (zh) 2011-04-20 2021-11-02 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
GB201412290D0 (en) * 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
RU2748278C2 (ru) * 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
CN107760779B (zh) 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Laurent David, 등, Circ Res. 2008, 102, 914~922*
Nicolas Ricard, BLOOD, 21 JUNE 2012, VOLUME119, NUMBER25, 6162~6171*

Also Published As

Publication number Publication date
CN106661094A (zh) 2017-05-10
US20170209540A1 (en) 2017-07-27
RU2017102381A3 (enExample) 2019-02-28
RU2733318C2 (ru) 2020-10-01
HRP20210734T1 (hr) 2021-06-11
DK3166628T3 (da) 2020-03-09
EP3669886B1 (en) 2021-02-24
HUE054512T2 (hu) 2021-09-28
SI3669886T1 (sl) 2021-08-31
EP3669886A1 (en) 2020-06-24
SMT202100323T1 (it) 2021-07-12
MX2020011333A (es) 2020-11-24
RU2017102381A (ru) 2018-08-10
ES2770073T3 (es) 2020-06-30
JP2017521074A (ja) 2017-08-03
ES2876124T3 (es) 2021-11-11
PT3166628T (pt) 2020-04-06
HRP20200418T1 (hr) 2020-06-26
PL3166628T5 (pl) 2023-11-27
PL3166628T3 (pl) 2020-06-15
RS61961B1 (sr) 2021-07-30
CA2954221C (en) 2023-02-14
EP3166628B1 (en) 2020-01-01
RS60181B1 (sr) 2020-06-30
HUE048924T2 (hu) 2020-09-28
JP6737770B2 (ja) 2020-08-12
BR112017000113A2 (pt) 2018-01-02
PT3669886T (pt) 2021-05-25
CY1124143T1 (el) 2022-05-27
US11572396B2 (en) 2023-02-07
WO2016005756A1 (en) 2016-01-14
ES2770073T5 (es) 2024-03-04
US10336800B2 (en) 2019-07-02
US20190359668A1 (en) 2019-11-28
EP3166628B2 (en) 2023-07-26
MX2017000448A (es) 2017-08-16
SI3166628T1 (sl) 2020-07-31
KR20230049757A (ko) 2023-04-13
AU2015287397A1 (en) 2017-02-16
EP3906936A1 (en) 2021-11-10
CY1123011T1 (el) 2021-10-29
LT3166628T (lt) 2020-04-10
AU2015287397B2 (en) 2020-08-20
US20170121383A1 (en) 2017-05-04
EP3166628A1 (en) 2017-05-17
KR20170029576A (ko) 2017-03-15
GB201412290D0 (en) 2014-08-27
CN106661094B (zh) 2020-09-08
LT3669886T (lt) 2021-06-10
MX378431B (es) 2025-03-10
US20240043485A1 (en) 2024-02-08
CA2954221A1 (en) 2016-01-14
DK3669886T3 (da) 2021-05-25
SMT202000171T1 (it) 2020-05-08
PL3669886T3 (pl) 2021-09-13

Similar Documents

Publication Publication Date Title
KR102519869B1 (ko) 골형성단백질의 치료적 용도
US8067388B2 (en) Decoy-containing pharmaceutical compositions and method of using the same
US20250064977A1 (en) Nucleic Acid-Based Compositions and Methods for Treating Small Vessel Diseases
CN117083381A (zh) 用于靶向炎性细胞或活化细胞和治疗或改善炎性病症和疼痛的组合物和方法
US20030228283A1 (en) Preventing secondary lymphedema with VEGF-D DNA
WO2017149306A1 (en) Combination therapy
HK40059883A (en) Bone morphogenetic proteins
JP2003250549A (ja) Ｎｋ４遺伝子または組換えｎｋ４蛋白質からなる医薬
HK40020167A (en) Bone morphogenetic proteins
HK40020167B (en) Bone morphogenetic proteins
HK1232462B (en) Therapeutic use of bone morphogenetic proteins
HK1232462A1 (en) Therapeutic use of bone morphogenetic proteins
BR112017000113B1 (pt) Polipeptídeo selecionado de uma variante da proteína morfogenética óssea (bmp9), composição farmacêutica e uso do mesmo
CN116253776A (zh) 靶向抑制trib3的多肽及其用途
AU2024342818A1 (en) Pharmaceutical composition for regenerating myocardium, suppressing myocardial fibrosis, or treating cardiac disease
CN116159126A (zh) 同源二聚体介导的C/EBPαS16磷酸化通过液-液相分离调节急性髓系白血病分化
MX2008009075A (en) Methods of treating or preventing tissue damage caused by increased blood flow
JP2009159883A (ja) 新規遺伝子治療薬

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170208

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200708

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220625

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230106

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230405

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230405

End annual number: 3

Start annual number: 1

PG1601 Publication of registration